Dana is a neurologist, neuroscientist and drug developer and brings more than 20 years of experience spanning biopharma, academia and government to his role as Chief Medical Officer (CMO) at Frequency. Over the course of his career, he has focused on the development of therapeutics for CNS conditions, as well as oncology, chronic pain, metabolic disorders and inflammatory conditions.

Before joining Frequency, Dana was the CMO of Lysosomal Therapeutics, working on a novel therapy for Parkinson’s Disease. Prior to that, he was the CMO for FORUM Pharmaceuticals, where he supported the development of therapies for the treatment of cognitive impairment in schizophrenia and Alzheimer’s disease. He served as the CMO and Senior Vice President of Clinical Research, Medical Affairs and Development for Ascend Therapeutics and is the former Vice President of Clinical Research for Guilford Pharmaceuticals. Earlier in his career Dana worked at Amgen as the director of clinical neurosciences. There he established the first clinical neuroscience group to investigate the potential therapeutic use of a variety of neurotrophic factors in neurodegenerative diseases.

Dana served on the staff of the National Institutes of Health for five years. He has co-authored more than 100 publications and book chapters in both basic and clinical neurosciences. Dana earned his M.D. from Tufts University School of Medicine and trained in internal medicine at Harvard Medical School and neurology at the Johns Hopkins Hospital.